Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies

Cancers

Matthew Mei¹  Yazeed Samara² 

[1] Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA;Division of Hematology and Medical Oncology, Harbor-UCLA Medical Center, Torrance, CA 90502, USA;

关键词: Hodgkin lymphoma;    autologous stem cell transplantation;    brentuximab vedotin;    nivolumab;    pembrolizumab;   

DOI  :  10.3390/cancers14071738

来源: DOAJ

【 摘 要 】

Standard treatment for relapsed and/or refractory (r/r) Hodgkin lymphoma (HL) consists of salvage therapy, historically consisting of multiagent cytotoxic chemotherapy, followed by autologous stem cell transplantation (autoHCT) in responding patients. With this approach, most patients can proceed to autoHCT, of whom approximately half are cured. However, the introduction of the novel agents brentuximab vedotin (BV) and the checkpoint inhibitors (CPI) nivolumab and pembrolizumab has changed the decision making and peri-transplant decision making, as early incorporation of one or more of these agents can reduce or even eliminate the need for cytotoxic chemotherapy prior to autoHCT. Furthermore, post-autoHCT maintenance therapy with BV has also been shown to decrease relapse in high-risk rel/ref HL patients. In this review, we survey the current data regarding autoHCT in HL with a focus on pre-autoHCT salvage as well as maintenance strategies, and we also talk about the emerging data challenging the long-held dogma of chemosensitivity being a requirement for successful autoHCT.

【 授权许可】

Unknown